Difference between revisions of "Rezvilutamide (SHR-3680)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
Warner-admin (talk | contribs) m (Text replacement - " (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT[0-9]{8})" to " [$1 Clinical Trials Registry]") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Prostate cancer]]=== | ===[[Prostate cancer]]=== | ||
| − | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. [https://doi.org/10.1016/s1470-2045(22)00507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36075260/ PubMed] https://clinicaltrials.gov/ct2/show/NCT03520478 | + | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. [https://doi.org/10.1016/s1470-2045(22)00507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36075260/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT03520478 Clinical Trials Registry] |
==Also known as== | ==Also known as== | ||
Revision as of 20:30, 17 June 2023
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. link to original article PubMed Clinical Trials Registry
Also known as
- Code name: SHR3680